CLINICAL AND MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB (SIE 2026) - Oct 6, 2026 - Abstract #MP08; "The recently developed R-PSS score may further assist clinicians in upfront treatment selection by providing prognostic stratification at the time of RUX initia- tion. In conclusion, RUX remains the most used JAKi in man- agement of MF, but cytopenic phenotypes and specific molecular lesions identify subsets of pts who may derive limited benefit, for whom alternative JAKi or early treatment reassessment may be warranted."
Clinical • Tumor mutational burden • Hematological Disorders • Myelofibrosis • ASXL1 • IDH1 • IDH2 • JAK1 • JAK2 • RAS • SRSF2 • TMB
|
|
Alessandro Laganà1; Massimo Breccia1
|